Interventional Cardiology Medical Group
Interventional Cardiology Medical Group
West Hills, California, United States13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Arrhythmias, Cardiac, Embolism and Thrombosis, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, stroke disorder, thrombotic disease, vascular disorder | Recruiting | Phase 2 | 2026-10-09 | NCT07175428 | |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Arrhythmias, Cardiac, Embolism and Thrombosis, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, stroke disorder, thrombotic disease, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07626411 | |
| Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, peripheral arterial disease, peripheral vascular disease, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07223593 | |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2026-10-05 | NCT06909565 | |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06531824 | |
| Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease | Arterial Occlusive Diseases, Embolism and Thrombosis, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, peripheral arterial disease, peripheral vascular disease, thrombotic disease, vascular disorder | Recruiting | Phase 3 | 2026-09-25 | NCT07318610 | |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Arrhythmias, Cardiac, Embolism, Embolism and Thrombosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic stroke, lung disorder, nervous system disorder, pulmonary embolism, respiratory system disorder, stroke disorder, thrombotic disease, vascular disorder, venous thromboembolism | Recruiting | Phase 3 | 2026-09-17 | NCT07430956 | |
| ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Acute Myocardial Infarction (AMI); Cardiovascular Risk | Active, not recruiting | Phase 3 | 2026-09-09 | NCT06118281 | |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-08-21 | NCT07136012 | |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-08-18 | NCT07567001 | |
| Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | acute myocardial infarction | Enrolling by invitation | Phase 3 | 2026-07-23 | NCT04957719 | |
| Lumason® Infusion vs. Bolus Administrations | cardiovascular disorder, heart disorder | Recruiting | Phase 3 | 2026-03-05 | NCT06400004 |